Resources

PxWire Volume 15, Issue 2

The field of HIV prevention is confronted with two opposing forces—programs for delivering PrEP have been shuttered all over the world by the withdrawal of the US government from global health while next-generation long-acting products have never held greater promise to accelerate HIV prevention and help the world achieve epidemic control. This issue provides a snapshot on threats to delivering PrEP, the potential of injectable lenacapavir (LEN) for PrEP, and on the implications of upstream research and development of other long-acting PrEP.

PrEP Delivery Imperiled

Programs for delivering PrEP have been shuttered all over the world by the withdrawal of the US government from global health. This graphic illustrates some of the severe measurable impacts of these cuts.

Modelling Shows the Potential of LA-PrEP

Modelling data from South Africa demonstrate the potential of injectable PrEP to dramatically reduce HIV incidence by up to 90% by 2044, and potentially even sooner with more aggressive uptake. This potential goes beyond South Africa, lighting the way toward epidemic control the world over.

An “Innovation Pile-Up” in Next-Generation LA-PrEP is Possible

The HIV prevention market is headed toward a period of significant opportunity—and possible congestion—as a slate of new products are on track for continued development and potential introduction to the market in 2027 and 2028. Markets and policies must be built to support the products in the market already, so that new options can be rapidly deployed and deliver impact. Otherwise, the field will squander time and money, with epidemic control slipping further out of reach.

Politics and Global Health: The Need for a New, Resilient Architecture

Recent, dramatic shifts in global health funding include cuts to US and UK foreign aid. This has had a cascade of devastating consequences on treatment and prevention programmes, including for HIV and TB across the globe. In a lecture at Oxford...

AVAC and FAPP Written Statement: US Senate Hearing on Biomedical Research

AVAC and GAPP submitted written testimony for the US Senate Appropriations Subcommittee’s April 30th hearing, “Biomedical Research: Keeping America’s Edge in Innovation.”

Research Matters Advocacy Toolkit

This toolkit for researchers shares key messages, practical advocacy guides, and resources to help move our collective efforts forward.

Years Ahead in HIV Prevention Research: Time to Market

This timeline shows the potential time points when the next-generation of HIV prevention options might find their way into new programs.

Lawsuit Wins and What’s at Stake

On February 10, AVAC led other organizations to sue  the US government including the President, the US State Department and USAID,  seeking emergency relief from an Executive Order that inhumanely froze all funding for foreign assistance. This case may well help to determine the future of foreign assistance, executive overreach, and the role of evidence, facts, and values in US policy.

AVAC’s Executive Director, Mitchell Warren and Public Citizen Litigator, Lauren Bateman explain these lawsuits and why they matter.

Better Engagement, Better Evidence

Writing in The Lancet Global Health, AVAC staffers Stacey Hannah, Jessica Salzwedel, and several co-authors, write about the importance of community stakeholder engagement clearly seen after World Health Organization adoption of new rules requiring clinical trials to improve this kind of coordination.